An Overview of Antivirals for Treating Lower Respiratory Tract Infections
DOI:
https://doi.org/10.29356/jmcs.v66i1.1657Keywords:
Antivirals, viral respiratory diseases, drug repurpose, drug researchAbstract
Abstract. Covid-19 has resulted in a worldwide epidemic (pandemic) with high morbidity and mortality, which has generated efforts in various areas of research looking for safe and effective treatments to combat the virus that generates this disease: SARS-CoV-2. However, several viruses have been emerged/adapted in the last few decades, also affecting the respiratory system. According to the world health organization (WHO), lower respiratory tract infections (LRTIs) are one of the leading causes of death worldwide, and viruses are playing important roles as the cause of these infections. In contrast to the vast repertoire of antibiotics that exist to treat bacteria-caused LRTIs, there are a very few antivirals approved for the treatment of virus-caused LRTIs, whose approach consists mainly of drug reuse. This minireview deals on the main viral pathogens that cause LRTIs and some of the most relevant antivirals to counter them (available drugs and molecules in research/clinical trials), with concise comments of their mechanism of action.
Resumen. Covid-19 ha resultado en una epidemia mundial (pandemia) con alta morbilidad y mortalidad, lo que ha generado esfuerzos en diversas áreas de investigación en la búsqueda de tratamientos seguros y eficaces para combatir el virus que genera esta enfermedad: el SARS-CoV-2. Sin embargo, un número de virus han surgido o se han adaptado en las últimas décadas, que también afectan el sistema respiratorio. Según la Organización Mundial de la Salud (OMS), las infecciones en vías respiratorias inferiores (LRTIs, por sus siglas en inglés) son una de las principales causas de muerte a nivel mundial, siendo los virus de los principales patógenos causantes de estas infecciones. En contraste con el repertorio amplio de antibióticos que existen para tratar LRTIs causadas por bacterias, existen muy pocos antivirales aprobados para su tratamiento, cuyo enfoque consiste principalmente en la reutilización de fármacos. Este ensayo consiste en una breve revisión de los principales agentes virales que causan LRTIs y de los antivirales más relevantes para combatir los virus que las causan (tanto fármacos disponibles como moléculas en fases de investigación o clínicas), con comentarios concisos sobre su mecanismo de acción.
Downloads
References
Al?Khalidi, F. Q.; Saatchi, R.; Burke, D.; Elphick, H.; Tan, S. Pediatr. Pulmonol. 2011, 46, 523-529.
Ionescu, C. M. The human respiratory system. In The human respiratory system, 1st ed.; Springer, 2013, pp 13-22.
Buhain, J.; Nahum, A. Cardiopulmonary Anatomy and Physiology. In Respiratory care: principles and practice, 2nd ed.; Hess, D., MacIntyre, N., Mishoe, S., Galvin, W., Adams, A. B. eds.; Jones & Bartlett Learning, 2012; pp 1109.
https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on june 25, 2021).
http://www.healthdata.org/mexico (accessed on june 25 2021).
Roser, M.; Ritchie, H.; Ortiz-Ospina, E.; Hasell, J. Excess mortality during the Coronavirus pandemic (COVID-19). https://ourworldindata.org/excess-mortality-covid (accessed on june 25, 2021).
Ahmad, F. B.; Cisewski, J. A.; Miniño, A.; Anderson, R. N.; Provisional Mortality Data — United States, 2020. MMWR Morb Mortal Wkly Rep 2021, 70, 519–522. DOI: http://dx.doi.org/10.15585/mmwr.mm7014e1 (accessed on june 25, 2021).
a) Dasaraju, P. V.; Liu, C; Infections of the Respiratory System In Medical Microbiology, 4th edition; Baron, S. Ed.; University of Texas Medical Branch at Galveston, 1996. https://www.ncbi.nlm.nih.gov/books/NBK8142/; b) Girard, M. P.; Cherian, T.; Pervikov, Y.; Kieny, M. P. Vaccine, 2005, 23, 5708-5724; c) Ho, Z. J. M.; Zhao, X.; Cook, A. R.; Loh, J. P.; Ng, S. H.; Tan, B. H.; Lee, V. J. Influenza Other Respir. Viruses. 2015, 9, 200-208.
a) Walsh, T. J.; Roilides, E.; Rex, J. H.; McGinnis, M. R. Mucormycosis. In Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd Edition; Guerrant, R. L., Walker, D. H., Weller, Peter F., Eds.; Elsevier Inc., 2011, 597–602; b) Chowdhary, A.; Agarwal, K.; Meis, J. F. PLoS pathogens. 2016; 12, e1005491.
Duffy, S.; Shackelton, L. A.; Holmes, E. C. Nat. Rev. Genet. 2008, 9, 267-276.
Antonelli, G.; Turriziani, O. Int. J. Antimicrob. Agents. 2012, 40, 95-102.
a) Carson, C.; Roper, R. World Economic Forum. Why are there so many drugs to kill bacteria, but so few to tackle viruses? https://www.weforum.org/agenda/2020/05/why-are-there-so-many-drugs-to-kill-bacteria-but-so-few-to-tackle-viruses/ (accessed on June 28, 2021); b) Colson, P.; Raoult, D. Int. J. Antimicrob. Agents, 2016, 48, 349; c) Dolin, R. Clin. Infect. Dis. 2011, 52, 438-439.
a) Smith, W.; Andrewes, C. H.; Laidlaw, P. P. Lancet, 1933, 66-68; b) Kilbourne, E. D. Hist. Philos. Life Sciences. 1992, 14, 299-308.
a) Nichols, W. G.; Peck Campbell, A. J.; Boeckh, M. Clin. Microbiol. Rev. 2008, 21, 274-290; b) Kesson, A. M. Paediatric Respir. Rev. 2007, 8, 240-248.
Rima, B.; Balkema-Buschmann, A.; Dundon, W. G.; Duprex, P.; Easton, A.; Fouchier, R.; Consortium, I. R. J. Gen. Virol. 2019, 100, 1593-1594.
Wang, L.-F.; Collins, P.L.; Fouchier, R.A.M.; Kurath, G.; Lamb, R.A.; Randall, R.E.; Rima, B.K. Paramyxoviridae. In Virus Taxonomy. Ninth report of the international Committee on Taxonomy of Viruses; King, A.M., Adams, M. J., Carsten, E.B., Lefkowittz, E.J., Eds.; Elsevier Inc., 2011; pp 672-685.
Takimoto, T.; Taylor, G. L.; Connaris, H. C. Crennell, S. J.; Portner, A. J. Virol. 2002, 76, 13028-13033.
a) Chanock, R.; Roizman, B.; Myers, R. Am. J. Epidemiol. 1957, 66, 281-290; b) Afonso, C. L.; Amarasinghe, G. K.; Bányai, K.; Bào, Y.; Basler, C. F.; Bavari, S.; Kuhn, J. H. Arch. Virol. 2016, 161, 2351-2360.
Morris, J. A.; Blount Jr, R. E.; Savage, R. E. Soc. Exp. Biol. Med. 1956, 92, 544-549.
a) Lamb, R. A.; Parks, G. D. Paramyxoviridae: The viruses and their replication. In Fields Virology; Knipe, D.M., Howley, P.M., Eds.; Lippincott Williams & Wilkins, 2007; pp 957-995; b) Falsey, A. R.; Walsh, E. E. Clin. Microbol. Rev. 2000, 13, 371-384; c) Collins, P. L.; Graham, B. S. J. Virol. 2008, 82, 2040-2055.
a) Mitra, R.; Baviskar, P.; Duncan-Decocq, R. R.; Patel, D.; Oomens, A. G. J. Virol. 2012, 86, 4432-4443; b) Ke, Z.; Dillard, R. S.; Chirkova, T.; Leon, F.; Stobart, C. C.; Hampton, C. M.; Wright, E. R. Viruses, 2018, 10, 446.
Borchers, A. T.; Chang, C.; Gershwin, M. E.; Gershwin, L. J. Clinic. Rev. Allerg. Immunol. 2013, 45, 331-379.
Falsey, A. R.; Walsh, E. E. Drugs Aging. 2005, 22, 577-587.
Boyoglu-Barnum, S.; Chirkova, T.; Anderson, L. J. Front. Immunol. 2019, 10, 1675.
https://www.cdc.gov/rsv/about/prevention.html (accessed on June 27, 2021).
Turner, T. L.; Kopp, B. T.; Paul, G.; Landgrave, L. C.; Hayes Jr, D.; Thompson, R. Clinico Econ.Outcomes Res. 2014, 6, 217-225.
Sidwell, R. W.; Huffman, J. H.; GP Khare, L.; Allen, B.; JT Witkowski, R.; Robins, K. Science. 1972, 177, 705-706.
Beaucourt, S.; Vignuzzi, M. Curr. Opin. Virol. 2014, 8, 10-15.
DeVincenzo, J. P.; McClure, M. W.; Symons, J. A.; Fathi, H.; Westland, C.; Chanda, S.; Fry, J. New Engl. J. Med. 2015, 373, 2048-2058.
Sudo, K.; Miyazaki, Y.; Kojima, N.; Kobayashi, M.; Suzuki, H.; Shintani, M.; Shimizu, Y. Antivir. Res. 2005, 65, 125-131.
Fearns, R.; Deval, J. Antivir. Res. 2016, 134, 63-76.
a) DeVincenzo, J. P.; Whitley, R. J.; Mackman, R. L.; Scaglioni-Weinlich, C.; Harrison, L.; Farrell, E.; Chien, J. W. New Engl. J. Med. 2014, 371, 711-722; b) Marty, F. M.; Chemaly, R. F.; Mullane, K. M.; Lee, D. G.; Hirsch, H. H.; Small, C. B.; Dadwal, S. S. Clin. Infect. Dis. 2020, 71, 2787-2795.
DeVincenzo, J.; Tait, D.; Efthimiou, J.; Mori, J.; Kim, Y. I.; Thomas, E.; Littler, E. Antimicrob. Agents Chemother. 2020, 64, e01884-19.
Zheng, X.; Gao, L.; Wang, L.; Liang, C.; Wang, B.; Liu, Y.; Yun, H. J. Med. Chem. 2019, 62, 6003-6014.
Lawrence, M. C.; Borg, N. A.; Streltsov, V. A.; Pilling, P. A.; Epa, V. C.; Varghese, J. N.; Colman, P. M. J. Mol. Biol. 2004, 335, 1343-1357.
a) Huberman, K.; Peluso, R. W.; Moscona, A. Virology, 1995, 214, 294-300; b) Villar, E.; Barroso, I. M. Glycoconj. J. 2006, 23, 5-17.
Henrickson, K. J.; Hoover, S.; Kehl, K. S.; Hua, W. Pediatr. Infect. Dis. J. 2004, 23, S11-S18.
Girard, M. P.; Cherian, T.; Pervikov, Y.; Kieny, M. P. Vaccine, 2005, 23, 5708-5724.
https://www.cdc.gov/parainfluenza/about/prevention-treatment.html (accessed on june 27 2021).
a) Alymova, I. V.; Taylor, G.; Takimoto, T.; Lin, T. H.; Chand, P.; Babu, Y. S.; Portner, A. Antimicrob. Agents Chemother. 2004, 48, 1495-1502; b) Chibanga, V. P.; Dirr, L.; Guillon, P.; El-Deeb, I. M.; Bailly, B.; Thomson, R. J.; von Itzstein, M. Antivir. Res. 2019, 167, 89-97.
Van den Hoogen, B. G.; de Jong, J. C.; Groen, J.; Kuiken, T.; de Groot, R.; Fouchier, R. A.; Osterhaus, A. D. Nat. Med. 2001, 7, 719-724.
a) Biacchesi, S.; Skiadopoulos, M. H.; Boivin, G.; Hanson, C. T.; Murphy, B. R.; Collins, P. L; Buchholz, U. J. Virology. 2003, 315, 1-9; b) Boivin, G.; Mackay, I.; Sloots, T. P.; Madhi, S.; Freymuth, F.; Wolf, D.; LeBlanc, É. Emerg. Infec. Dis. 2004, 10, 1154-1157.
van den Hoogen, B. G.; Bestebroer, T. M.; Osterhaus, A. D.; Fouchier, R. A. Virology, 2020, 295, 119-132.
a) Wei, Y.; Zhang, Y.; Cai, H.; Mirza, A. M.; Iorio, R. M.; Peeples, M. E.; Li, J. J. Virol. 2014, 88, 4338-4352; b) Connolly, S. A.; Leser, G. P.; Yin, H. S.; Jardetzky, T. S.; Lamb, R. A. PNAS, 2006, 103, 17903-17908.
Wyde, P. R.; Moylett, E. H.; Chetty, S. N.M.; Jewell, A.; Bowlin, T. L.; Piedra, P. A. Antivir. Res. 2004, 63, 51-59.
Fujita, A.; Kan-o, K.; Tonai, K.; Yamamoto, N.; Ogawa, T.; Fukuyama, S.; Matsumoto, K. Front. Immunol. 2020, 11, 432.
Bailly, B.; Gorle, A.; Dirr, L.; Malde, A.; Farrell, N. P.; Berners-Price, S.; von Itzstein, M. Chem. Commun. 2021, 57, 4666-4669.
Isaeva, E. I.; Nebol'sin, V. E.; Kozulina, I.; Morozova, O. V. Vopr. Virusol. 2012, 57, 34-38.
McCauley J.W.; Hongo S.; Kaverin N.V.; Kochs G.; Lamb R.A.; Smith, G.J.D. Orthomyxoviridae. In Virus Taxonomy. Ninth report of the international Committee on Taxonomy of Viruses; King, A.M., Adams, M. J., Carsten, E.B., Lefkowittz, E.J., Eds.; Elsevier, 2012; pp 749-761.
Mahal, A.; Duan, M.; Zinad, D. S.; Mohapatra, R. K.; Obaidullah, A. J.; Wei, X.; ... Zhu, Q. RSC Adv. 2021, 11, 1804-1840.
https://www.cdc.gov/flu/about/viruses/types.htm (accessed on June 28, 2021).
Clearly, this asseveration was valid before Covid-19 pandemic, which was caused by SARS-CoV-2 coronavirus.
a) Tognotti, E. J. Infect. Dev. Ctries, 2009, 3, 331-334; b) Dawood, F. S.; Iuliano, A. D.; Reed, C.; Meltzer, M. I., Shay, D. K.; Cheng, P. Y., Widdowson, M. A. Lancet Infect. Dis. 2012, 12, 687-695.
McGeoch, D.; Fellner, P.; Newton, C. PNAS 1976, 73, 3045-3049; b) Gamblin, S. J.; Skehel, J. J. J. Biol. Chem. 2010, 285, 28403-28409; c) Janakiraman, M. N.; White, C. L.; Laver, W. G.; Air, G. M.; Luo, M. Biochemistry, 1994, 33, 8172-8179.
https://www.who.int/immunization/research/development/influenza/en/ (accessed on June 28, 2021).
Paules, C. I.; Sullivan, S. G.; Subbarao, K.; Fauci, A. S. New Engl. J. Med. 2018, 378, 7-9.
Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Stevens, R. C. J. Med. Chem. 1998, 41, 2451-2460.
https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information (accessed on June 28, 2021).
a) Kim, J. H.; Resende, R.; Wennekes, T.; Chen, H. M.; Bance, N.; Buchini, S.; Withers, S. G. Science, 2013, 340, 71-75; b) Zhang, J.; Murugan, N. A.; Tian, Y.; Bertagnin, C.; Fang, Z.; Kang, D.; Liu, X. J. Med. Chem. 2018, 61, 9976-9999.
a) Basu, A.; Antanasijevic, A.; Wang, M.; Li, B.; Mills, D. M.; Ames, J. A.; Bowlin, T. L. J. Virol. 2014, 88, 1447-1460; b) Yuan, S.; Wen, L.; Zhou, J. ACS Infect. Diseases. 2018, 4, 218-223; c) Taieb, V.; Ikeoka, H.; Ma, F. F.; Borkowska, K.; Aballéa, S.; Tone, K.; Hirotsu, N. Curr. Med. Res. Opin. 2019, 35, 1355-1364.
McGuire, K. L.; Hogge, J.; Hintze, A.; Liddle, N.; Nelson, N.; Pollock, J.; Busath, D. D. Copper complexes as influenza antivirals: reduced zebrafish toxicity. In Engineered Nanomaterials: Health and Safety; Avramescu, S. M., Fierascu, I., Akhtar, K., Eds.; IntechOpen, 2019; pp 1-15.
Han, J.; Perez, J.; Schafer, A.; Cheng, H.; Peet, N.; Rong, L.; Manicassamy, B. Curr. Med. Chem. 2018, 25, 5115-5127.
a) Siddell, S. G.; Anderson, R.; Cavanagh, D.; Fujiwara, K.; Klenk, H. D.; Macnaughton, M. R.; Van der Zeijst, B. A. M. Intervirology. 1983, 20, 181-189; b) Aragón-Nogales, R.; Vargas-Almanza, I.; Miranda-Novales, M. G. Rev. Mex. Pediatr. 2019, 86, 213-218.
de Groot, R. J.; Baker, S. C.; Baric, R.; Enjuanes, L.; Gorbalenya, A. E.; Holmes, K. V.; …; Ziebuhr, J. Coronaviridae. In Virus Taxonomy. Ninth report of the international Committee on Taxonomy of Viruses; King, A. M., Adams, M. J., Carsten, E. B., Lefkowittz, E. J., Eds.; Elsevier, 2011; pp 806-828.
Lim, Y. X.; Ng, Y. L.; Tam, J. P.; Liu, D. X. Diseases, 2016, 4, 26.
Anand, K. Science, 2003, 300, 1763–1767.
a) Schalk, A. F. J. Am. Vet. Med. Assoc. 1931, 78, 413-423; b) Bushnell, L. D.; Brandly, C. A. Poul. Sci. 1933, 12, 55-60; c) Gibbs, C. S. Science. 1935, 81, 345-346.
a) Beach, J. R.; Schalm, O. W. Poultry Sci. 1936, 15, 199-206. b) Lecoq, H. C. R. Acad. Sci., Ser. III. 2001, 324, 929-933.
Tyrrell, D. A. J.; Bynoe, M. L. Br. Med. J. 1965, 1, 1467.
a) Van Der Hoek, L.; Pyrc, K.; Jebbink, M. F.; Vermeulen-Oost, W.; Berkhout, R. J.; Wolthers, K. C.; Berkhout, B. Nat. Med. 2004, 10, 368-373; b) Wege, H.; Ter Meulen, V. Curr. Top. Microbiol. Immunol. 1982, 165-200; c) Corman, V. M.; Muth, D.; Niemeyer, D.; Drosten, C. Adv. Virus Res. 2018, 100, 163-188; d) Myint S. H. Rev. Med. Virol. 1994, 4, 35-46.
a) Almeida, J. D.; Tyrrell, D. A. J. J. Gen. Virol. 1967, 1, 175-178; b) Almeida, J. D.; Berry, D. M.; Cunningham, C. H.; Hamre, D.; Hofstad, M. S.; Mallucci, L.; Tyrrell, D. A. J. Nature. 1968, 220, 650.
a) Yeager, C. L.; Ashmun, R. A.; Williams, R. K.; Cardellichio, C. B.; Shapiro, L. H.; ...; Holmes, K. V. Nature 1992, 357, 420-422. b) Kolb, A. F.; Maile, J.; Heister, A.; Siddell, S. G. J. Gen. Virol. 1996, 77, 2515-2521.
Tyrrell, D. A.; Almeida, J. D.; Cunningham, C. H.; Dowdle, W. R.; Hofstad, M. S.; McIntosh, K.; Bingham, R. W. Intervirology. 1975, 5, 76-82.
Zhu, Z.; Meng, K.; Meng, G. Sci. Rep. 2020, 10, 21617.
Peiris, J. S. M. Coronaviruses. Med. Microbiol. 2012, 587-593.
Liu, D. X.; Liang, J. Q.; Fung, T. S. Human coronavirus-229E, -OC43,-NL63, and-HKU1. In Encyclopedia of Virology. 4th edition; Bamford D.H; Zuckerman M. Ed.; Elsevier Ltd 2021, 428-440.
Vlasova, A. N.; Kenney, S. P.; Jung, K.; Wang, Q.; Saif, L. J. Front. Ver. Sci. 2021, 626785.
Zeng, Z. Q.; Chen, D. H.; Tan, W. P.; Qiu, S. Y.; Xu, D.; Liang, H. X.; Zhou, R. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 363-369.
a) Carbajo-Lozoya, J.; Müller, M. A.; Kallies, S.; Thiel, V.; Drosten, C.; Von Brunn, A. Virus Res. 2012, 165, 112-117; b) Pillaiyar, T.; Meenakshisundaram, S.; Manickam, M. Drug Discov. Today, 2020, 25, 668-688; c) Zandi, K.; Amblard, F.; Musall, K.; Downs-Bowen, J.; Kleinbard, R.; Oo, A.; Schinazi, R. F. Antimicrob. Agents Chemother. 2020, 65, e01652-20.
Raj, V. S.; Osterhaus, A. D.; Fouchier, R. A.; Haagmans, B. L. Curr. Opin. Virol. 2014, 5, 58-62.
Reusken, C. B.; Haagmans, B. L.; Müller, M. A.; Gutierrez, C.; Godeke, G. J.; Meyer, B.; Koopmans, M. P. Lancet Infect. Dis. 2013, 13, 859-866.
a) https://www.who.int/emergencies/mers-cov/en/ (accessed on July 05, 2021); b) Ramadan, N.; Shaib, H. Germs, 2019, 9, 35-42.
www.cdc.gov/coronavirus/mers/ (accessed on July 5, 2021).
a) Ren, Z.; Yan, L.; Zhang, N.; Guo, Y.; Yang, C.; Lou, Z.; Rao, Z. Protein Cell. 2013, 4, 248-250; b) Tomar, S.; Johnston, M. L.; John, S. E. S.; Osswald, H. L.; Nyalapatla, P. R.; Paul, L. N.; Mesecar, A. D. J. Biol. Chem. 2015, 290, 19403-19422.
Rossignol, J. F. J. Infect. Public health. 2016, 9, 227-230; b) Rossignol, J. F. Antivir. Res. 2014, 110, 94-103.
Hart, B. J.; Dyall, J.; Postnikova, E.; Zhou, H.; Kindrachuk, J.; Johnson, R. F.; Jahrling P. B.; Hensley, L. J. Gen. Virol. 2014, 95, 571-577; b) Taban Akça, K. E. V. S. E. R.; Süntar, ?. Gazi Med. J. 2020, 31, 478-484; c) Park, J. Y.; Yuk, H. J.; Ryu, H. W.; Lim, S. H.; Kim, K. S.; Park, K. H.; Lee, W. S. J. Enzyme Inhib. Med. Chem. 2017, 32, 504-512; d) Chan, J. F.; Chan, K. H.; Kao, R. Y.; To, K. K.; Zheng, B. J.; Li, C. P., Yuen, K. Y. J. Infect. 2013, 67, 606-616.
Feng, Y.; Gao, G. F. Comp. Immunol. Microbil. Infect. Dis. 2007, 30, 309-327.
https://www.who.int/csr/sars/country/table2003_09_23/en/ (accessed on July 5, 2021).
a) Snijder, E. J.; Bredenbeek, P. J.; Dobbe, J. C.; Thiel, V.; Ziebuhr, J.; Poon, L. L.; Gorbalenya, A. E. J. Mol. Biol. 2003, 331, 991-1004; b) Fouchier, R. A.; Hartwig, N. G.; Bestebroer, T. M.; Niemeyer, B.; De Jong, J. C.; Simon, J. H.; Osterhaus, A. D. PNAS. 2004, 101, 6212-6216.
Graham, R. L.; Donaldson, E. F.; Baric, R. S. Nat. Rev. Microbiol. 2013 11, 836-848.
a) Pillaiyar, T.; Manickam, M.; Namasivayam, V.; Hayashi, Y.; Jung, S. H. J. Med. Chem. 2016, 59, 6595-6628; b) Akaji, K.; Konno, H. Molecules. 2016, 25, 3920. c) Liu, Y.; Liang, C.; Xin, L.; Ren, X.; Tian, L.; Ju, X.; Jian, Y. Eur. J. Med. Chem. 2020, 206, 112711.
Yang, Q.; Chen, L.; He, X.; Gao, Z.; Shen, X.; Bai, D. Chem. Pharm. Bull. 2008, 56, 1400-1405.
Kao, R. Y.; Tsui, W. H.; Lee, T. S.; Tanner, J. A.; Watt, R. M.; Huang, J. D.; Yuen, K. Y. Chem. Biol. 2004, 11, 1293-1299.
https://coronavirus.jhu.edu/map.html (Accessed on July 6 2021).
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. Nature Microbiol. 2020, 5, 536-534.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ events-as-they-happen (accessed on July 6, 2021).
a) Zhou, P.; Yang, X. L.; Wang, X. G.; Hu, B.; Zhang, L.; Zhang, W.; Shi, Z. L. Nature, 2020, 579, 270-273; b) Xu, X.; Chen, P.; Wang, J.; Feng, J.; Zhou, H.; Hao P. Sci China Life Sci. 2020, 63, 457-460.
Khailany, R. A.; Safdar, M.; Ozaslan, M. Gene reports. 2020, 19, 100682.
https://covid19.who.int/ (accessed on July 6, 2021).
a) Poorolajal, J. J. Res. Health Sci. 2021, 21, e00502 b) https://ceufast.com/blog/the-deadliest-pandemics-in-history (accessed on July 8, 2021).
https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html (accessed on July 8, 2021).
https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines (accessed on July 8, 2021).
a) Ahidjo, B. A.; Loe, M. W. C.; Ng, Y. L.; Mok, C. K.; Chu, J. J. H. ACS Infect. Dis. 2020, 6, 1624-1634; b) Morse, J. S.; Lalonde, T.; Xu, S.; Liu, W. R. Chembiochem. 2020, 21, 730.
Zhou, H.; Fang, Y.; Xu, T.; Ni, W. J.; Shen, A. Z.; Meng, X. M. Brit. J. Pharmacol. 2020, 177, 3147-3161.
a) Devaux, C. A.; Rolain, J. M.; Colson, P.; Raoult, D. Int. J. Antimicrob. Agents. 2020, 55, 105938; b) Bignardi, P. R.; Vengrus, C. S.; Aquino, B. M.; Cerci Neto, A. Pathog. Glob. Health. 2021, 115, 139-150.
a) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (accessed on October 9, 2021); b) Goldman, A.; Bomze, D.; Dankner, R.; Hod, H.; Meirson, T.; Boursi, B.; Maor, E. Br. J. Clin. Pharmacol. 2021, 87, 1432-1442; c) Bignardi, P. R.; Vengrus, C. S.; Aquino, B. M.; Cerci Neto, A. Pathog. Global Health 2021, 115, 139-150; d) Axfors, C.; Schmitt, A. M.; Janiaud, P.; van’t Hooft, J.; Abd-Elsalam, S., Abdo, E. F.; ... Hemkens, L. G. Nat. Commun. 2021, 12, 1-13.
a) Stebbing, J.; Krishnan, V.; de Bono, S.; Ottaviani, S.; Casalini, G.; Richardson, P. J.; Sacco Baricitinib Study Group. EMBO Mol. Med. 2020, 12, e12697; b) Buckley, L. F.; Wohlford, G. F.; Ting, C.; Alahmed, A.; Van Tassell, B. W.; Abbate, A.; Libby, P. Crit. Care Explor. 2020, 2, e0178; c) Kalil, A. C.; Patterson, T. F.; Mehta, A. K. N. Engl. J. Med. 2021, 384, 795-807.
Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Science, 2020, 367, 1444-1448.
a) Gurwitz, D. Drug Dev. Res. 2020, 81, 537-540; b) Offringa, A.; Montijn, R.; Singh, S.; Paul, M.; Pinto, Y. M.; Pinto-Sietsma, S. J. Eur. Heart J. Cardiovasc. Pharmacother. 2020, 6, 317-325; c) de Ligt, M.; Hesselink, M. K.; Jorgensen, J.; Jocken, J. W.; Blaak, E. E.; Goossens, G. H. Obesity. 2021, DOI: 10.1002/oby.23221.
a) Maiti, B. K. ACS Pharmacol. Transl. Sci. 2020, 3, 783-785; b) Chowdhury, S. M.; Talukder, S. A.; Khan, A. M.; Afrin, N.; Ali, M. A.; Islam, R.; Halim, M. A. J. Phys. Chem. B, 2020, 124, 9785-9792.
Schütz, D.; Ruiz-Blanco, Y. B.; Münch, J.; Kirchhoff, F.; Sanchez-Garcia, E.; Müller, J. A. Adv. Drug Deliv. Rev. 2020, 167, 47-65.
a) Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Müller, M. A. Cell. 2020, 181, 271-280; b) Hoffmann, M.; Kleine-Weber, H.; Pöhlmann, S. Molecular Cell. 2020, 78, 779-784.
Gil?Moles, M.; Basu, U.; Büssing, R.; Hoffmeister, H.; Türck, S.; Varchmin, A.; Ott, I. Chem. Eur J. 2020, 26, 15140-15144.
Rajpoot, S.; Alagumuthu, M; Baig, M. S. Curr. Res. Struct. Biol. 2021, 3, 9-18.
a) Sisay, M. Pharmacol. Res. 2020, 156, 104779; b) Choy, K. T.; Wong, A. Y. L.; Kaewpreedee, P.; Sia, S. F.; Chen, D.; Hui, K. P. Y.; Peiris, M. Antivir. Res. 2020, 178, 104786.
a) Kim, E. J.; Choi, S. H.; Park, J. S.; Kwon, Y. S.; Lee, J.; Kim, Y.; Choi, E. Y. Yonsei Med. J. 2020, 61, 826-830; b) http://www.sd.chinanews.com/2/2020/0205/70145.html (accessed in July 8, 2021).
Vatansever, E. C.; Yang, K. S.; Drelich, A. K.; Kratch, K. C.; Cho, C. C.; Kempaiah, K. R.; Liu, W. R. PNAS, 2021, 118, e2012201118.
Niesor, E. J.; Boivin, G.; Rhéaume, E.; Shi, R.; Lavoie, V.; Goyette, N.; Tardif, J. C. ACS Omega. 2021, 6, 16584-165591.
Vuong, W.; Khan, M. B.; Fischer, C.; Arutyunova, E.; Lamer, T.; Shields, J.; Lemieux, M. J. Nat. Commun. 2020, 11, 1-8.
Ma, C.; Sacco, M. D.; Hurst, B.; Townsend, J. A.; Hu, Y.; Szeto, T.; Wang, J. Cell Res. 2020, 30, 678-692.
a) Yamashima, T. Prog. Neurobiol. 2013, 105, 1-23; b) David, L. L.; Shearer, T. R.; Shih, M. J. Biol. Chem. 1993, 268, 1937-1940.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral (accessed on July 9, 2021).
de Vries, M.; Mohamed, A. S.; Prescott, R. A.; Valero-Jimenez, A. M.; Desvignes, L.; O’Connor, R.; Dittmann, M. J. Virol. 2021, 95, e01819-20.
Gao, Y.; Yan, L.; Huang, Y.; Liu, F.; Zhao, Y.; Cao, L.; Rao, Z. Science. 2020, 368, 779-782.
a) Sheahan, T. P.; Sims, A. C.; Zhou, S.; Graham, R. L.; Pruijssers, A. J.; Agostini, M. L.; Baric, R. S. Sci. Transl. Med. 2020, 12, eabb5883; b) Painter, W. P.; Holman, W.; Bush, J. A.; Almazedi, F.; Malik, H.; Eraut, N. C.; ... Painter, G. R. Antimicrob. Agents Chemother. 2021, 65, e02428-20.
Zanella, I.; Zizioli, D.; Castelli, F.; Quiros-Roldan, E. Pharmaceuticals. 2021, 14, 454.
Elfiky, A. A. Life Sci. 2020, 253, 117592.
a) Nourian, A.; Khalili, H.; Ahmadinejad, Z.; Kouchak, H. E.; Jafari, S.; Manshadi, S. A. D.; Kebriaeezadeh, A. Acta Bio Medica: Atenei Parmensis. 2020, 91, e2020102; b) Chen, Y. W.; Yiu, C. P. B.; Wong, K. Y. F1000Research. 2020, 9, 129.
Simmons, B.; Wentzel, H.; Mobarak, S.; Eslami, G.; Sadeghi, A.; Ali Asgari, A.; Hill, A. J. Antimicrob. Chemother. 2021, 76, 286-291.
a) https://www.science.org/content/blog-post/molnupiravir-thor-s-hammer-delivers (accessed on October 3, 2021); b) https://www.bbc.com/news/health-58764440 (accessed on October 3, 2021); c) https://www.sciencenews.org/article/coronavirus-covid-antiviral-pill-merck-molnupiravir-hospitalization-death; (accessed on October 3, 2021).
a) https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment (accessed on July 8, 2021); b) https://www.fda.gov/ media/137566/download (accessed on July 8, 2021).
Agostini, M. L.; Andres, E. L.; Sims, A. C.; Graham, R. L.; Sheahan, T. P.; Lu, X.; Denison, M. R. mBio. 2018, 9, e00221-18.
a) Gordon, C. J.; Tchesnokov, E. P.; Feng, J. Y.; Porter, D. P.; Götte, M. J. Biol. Chem. 2020, 295, 4773-4779; b) Saha, A.; Sharma, A. R.; Bhattacharya, M.; Sharma, G.; Lee, S. S.; Chakraborty, C. Pharmacol. Res. 2020, 158, 104904.
Harrach, B.; Benkö, M.; Both, G.W.; Brown, M.; Davison, A.J.; Echavarría, M.; Wadell, G. Adenoviridae, in Virus Taxonomy. Ninth report of the international Committee on Taxonomy of Viruses, King, A.M.; Adams, M. J.; Carsten, E.B.; Lefkowittz, E.J., Eds.; Elsevier 2012, 125-141.
Davison, A. J.; Benk?, M.; Harrach, B. J. Gen. Virol. 2003, 84, 2895-2908.
https://www.cdc.gov/adenovirus/index.html (accessed on July 8, 2021).
San Martín, C. Viruses. 4, 2012, 847-877.
https://www.cdc.gov/adenovirus/hcp/prevention-treatment.html (accessed on July 9, 2021).
Naesens, L.; Lenaerts, L.; Andrei, G.; Snoeck, R.; Van Beers, D.; Holý, A.; De Clercq, E. Antimicrob. Agents. Chemother. 2005, 49, 1010-1016.
a) https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm b) Chen, W.; Mook Jr, R. A.; Premont, R. T.; Wang, J. Cell. Signal. 2018, 41, 89-96.
a) Xu, J.; Berastegui-Cabrera, J.; Carretero-Ledesma, M.; Chen, H.; Xue, Y.; Wold, E. A.; Sánchez-Céspedes, J. Int. J. Mol. Sci. 2021, 22, 1617; b) Kumaki, Y.; Woolcott, J. D.; Roth, J. P.; Mclean, T. Z.; Smee, D. F.; Barnard, D. L.; ... Hostetler, K. Y. Antivir. Res. 2018, 158, 122-126; c) Wold, W. S.; Tollefson, A. E.; Ying, B.; Spencer, J. F.; Toth, K. FEMS Microbiol. Rev. 2019, 43, 380-388; d) Jaros, S. W.; Król, J.; Ba?anów, B.; Poradowski, D. Molecules 2020, 25, 2119; e) Xu, J.; Berastegui-Cabrera, J.; Chen, H.; Pachón, J.; Zhou, J.; Sánchez-Céspedes, J. J. Med. Chem. 2020, 63, 3142-3160.
a) Tatsis, N.; Ertl, H. C. Mol. Ther. 2004, 10, 616-629; b) Kobinger, G. P.; Feldmann, H.; Zhi, Y.; Schumer, G.; Gao, G.; Feldmann, F.; Wilson, J. M. Virology. 2006, 346, 394-401.
Zhu, F. C.; Hou, L. H.; Li, J. X.; Wu, S. P.; Liu, P.; Zhang, G. R.; Chen, W. Lancet. 2015, 385, 2272-2279.
Shiver, J. W.; Emini, E. A. Annu. Rev. Med. 2004, 55, 355-372.
a) Zhu, F. C.; Guan, X. H.; Li, Y. H.; Huang, J. Y.; Jiang, T.; Hou, L. H.; Chen, W. Lancet. 2020, 396, 479-488; b) Wu, S.; Zhong, G.; Zhang, J.; Shuai, L.; Zhang, Z.; Wen, Z.; ... Chen, W. Nat. Commun. 2020, 11, 1-7.
Lasaro, M. O.; Ertl, H. C. Mol. Ther. 2009, 17, 1333-1339; b) https://cen.acs.org/pharmaceuticals/vaccines/CanSino-publishes-first-COVID-19/98/i21 (Accessed on July 9, 2021).
a) Geisbert, T. W.; Bailey, M.; Hensley, L.; Adideu, C.; Geisbert, J.; Stanley, D.; Sullivan, N. J. J. Virol. 2011, 85, 4222-4233. b) https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html (accessed on August 10, 2021).
Atmar, R. L.; Piedra, P. A.; Patel, S. M.; Greenberg, S. B.; Couch, R. B.; Glezen, W. P. J. Clin. Microbiol. 2012, 50, 506-508.
a) Knowles, N. J.; Hovi, T, Hyypiä, T.; King, A. M. Q.; Lindberg, A. M.; Pallansch, M. A.; Zell, R. Picornaviridae. In Virus Taxonomy. Ninth report of the internationalCommittee on Taxonomy of Viruses; King, A. M., Adams, M. J., Carsten, E. B., Lefkowittz, E. J., Eds.; Elsevier, 2012; pp 855-880; b) Wimmer, E. Cell, 1982, 28, 199-201.
Rotbart, H. A.; Hayden, F. G. Arch. Fam. Med. 2000, 9, 913-920.
Hayden, F. G. Rev. Med. Virol. 2004, 14, 17-31.
Jacobs, S. E.; Lamson, D. M.; George, K. S.; Walsh, T. J. Clin. Microbiol. Rev. 2013, 26, 135-162.
a) Pitkäranta, A.; Hayden, F. G. Ann. Med. 1998, 30, 529-537; b) Palmenberg, A. C.; Rathe, J. A.; Liggett, S. B. J. Allergy Clin. Immunol. 2010, 125, 1190-1199.
Greve, J. M.; Davis, G.; Meyer, A. M.; Forte, C. P.; Yost, S. C.; Marlor, C. W.; McClelland, A. Cell, 1989, 56, 839-847.
Pevear, D. C.; Fancher, M. J.; Felock, P. J.; Rossmann, M. G.; Miller, M. S.; Diana, G.; Dutko, F. J. J. Virol. 1989, 63, 2002-2007.
a) Pevear, D. C.; Hayden, F. G.; Demenczuk, T. M.; Barone, L. R.; McKinlay, M. A.; Collett, M. S. Antimicrob. Agents Chemother. 2005, 49, 4492-4499; b) Senior, K. Lancet Infect. Dis. 2002, 2, 264.
Lanko, K.; Sun, L.; Froeyen, M.; Leyssen, P., Delang, L.; Mirabelli, C.; Neyts, J. Antivir. Research. 2021, 105177; b) Lacroix, C.; George, S.; Leyssen, P.; Hilgenfeld, R.; Neyts, J. Antimicrob. Agents Chemother. 2015, 59, 5814-5818.
Krenn, B. M.; Gaudernak, E.; Holzer, B.; Lanke, K.; Van Kuppeveld, F. J. M.; Seipelt, J. J. Virol. 2009, 83, 58-64.
Cotmore, S. F.; Agbandje-McKenna, M.; Canuti, M.; Chiorini, J. A.; Eis-Hubinger, A. M.; Hughes, J.; Consortium, I. R. J. Gen. Virol. 2019, 100, 367-368.
Tijssen, P.; Agbandje-McKenna, M.; Almendral, J. M.; Bergoin, M.; Flegel, T. W.; Hedman, K.; Tattersall, P. Parvoviridae. In Virus Taxonomy. Ninth report of the international Committee on Taxonomy of Viruses; King, A. M., Adams, M. J., Carsten, E. B., Lefkowittz, E. J., Eds.; Elsevier, 2012; pp. 405-425.
Allander, T.; Tammi, M. T.; Eriksson, M.; Bjerkner, A.; Tiveljung-Lindell, A.; Andersson, B. PNAS. 2005, 102, 12891-12896.
Moreno, C.; Solís, Y.; ORyan, M. Rev. Chilena Infectol. 2009, 26, 504-510.
Schildgen, V.; Longo, Y.; Pieper, M.; Schildgen, O. Influenza other Respir. Viruses. 2018, 12, 667-668.
Christensen, A.; Kesti, O.; Elenius, V.; Eskola, A. L.; Døllner, H.; Altunbulakli, C.; Jartti, T. Lancet Child Adolesc. Health. 2019, 3, 418-426.
Edwards, A.; Hartung, I. V. Science. 2021, 373, 488-489.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
